Related Experiment Video
Updated: Jan 27, 2026
05:51
Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease
Published on: October 14, 2021
4.4K
Extended-Release Amantadine for Levodopa-Induced Dyskinesia
Khashayar Dashtipour1, Ali R Tafreshi1,2, Rajesh Pahwa3
1a Department of Neurology , Loma Linda University School of Medicine , Loma Linda , CA , USA.
Expert Review of Neurotherapeutics
|March 21, 2019
Summary
Amantadine extended release (ER) is the only FDA-approved treatment for levodopa-induced dyskinesia (LID) in Parkinson's disease (PD). This therapy effectively reduces LID and improves motor function, allowing for more sustainable levodopa use.
Area of Science:
- Neurology
- Movement Disorders
- Pharmacology
Background:
- Levodopa-induced dyskinesia (LID) significantly limits long-term levodopa therapy for Parkinson's disease (PD).
- Effective and safe treatments for LID are scarce, highlighting a critical unmet need in PD management.
- Amantadine extended release (ER) is the sole FDA-approved medication specifically for LID treatment.
Purpose of the Study:
- To review the efficacy and safety of amantadine ER in managing LID.
- To provide expert perspectives on the clinical use and future potential of amantadine ER for PD patients.
- To assess amantadine ER's role in improving therapeutic outcomes and levodopa therapy sustainability.
Main Methods:
- Review of clinical trial data on amantadine ER for LID treatment.
- Analysis of safety and efficacy profiles of amantadine ER.
- Expert opinion synthesis on current and future applications of amantadine ER.
Main Results:
- Amantadine ER has demonstrated efficacy in reducing LID in clinical trials.
- Amantadine ER has also been shown to decrease "OFF" time in Parkinson's disease patients.
- The medication is considered safe for managing LID, supporting sustained levodopa therapy.
Conclusions:
- Amantadine ER is a valuable therapeutic option for controlling LID in Parkinson's disease.
- This treatment can enhance the sustainability of levodopa therapy, improving patient outcomes.
- Further research and clinical application of amantadine ER hold promise for PD management.
Related Concept Videos
01:28Energy-releasing Steps of Glycolysis
146.7K
Glycolysis is divided into two phases based on whether energy is utilized or released. While the first phase consumes ATP, the second phase produces energy in the form of ATP and NADH. The energy is released over a sequence of reactions that turns G3P into pyruvate. The energy-releasing phase—steps 6-10 of glycolysis—occurs twice, once for each of the two 3-carbon sugars produced during steps 1-5 of the first phase.
The first energy-releasing step—the 6th step of glycolysis...
The first energy-releasing step—the 6th step of glycolysis...
146.7K
01:07Gravitational Potential Energy for Extended Objects
2.0K
Consider a system comprising several point masses. The coordinates of the center of mass for this system can be expressed as the summation of the product of each mass and its position vector divided by the total mass:
2.0K
01:21Drugs Affecting Neurotransmitter Release or Uptake
1.6K
Certain drugs can affect how neurotransmitters called catecholamines, are released or taken back up in the adrenergic neuron. They can have different effects on the body's sympathetic transmission. Reserpine, a natural compound found in the Rauwolfia shrub, blocks a transporter called vesicular monoamine transporter (VMAT), which leads to a buildup of catecholamines in the cell and reduces sympathetic transmission. Another drug called guanethidine works in multiple ways, including blocking...
1.6K
01:31ATP Energy Storage and Release
14.3K
ATP is a highly unstable molecule. Unless quickly used to perform work, ATP spontaneously dissociates into ADP and inorganic phosphate (Pi), and the free energy released during this process is lost as heat. The energy released by ATP hydrolysis is used to perform work inside the cell and depends on a strategy called energy coupling. Cells couple the exergonic reaction of ATP hydrolysis with endergonic reactions, allowing them to proceed.
One example of energy coupling using ATP involves a...
One example of energy coupling using ATP involves a...
14.3K
01:13Induced-fit Model
89.1K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
89.1K
01:10In Vitro Drug Release Testing: Overview, Development and Validation
327
In vitro dissolution and drug release tests assess how quickly and how much of a drug is released from its dosage form into an aqueous medium under standardized laboratory conditions. These tests are essential tools in pharmaceutical development and quality assurance, offering insight into the drug's performance before clinical use.During formulation development, dissolution testing identifies incomplete or inconsistent drug release issues. It also supports decisions on selecting the optimal...
327